<DOC>
	<DOCNO>NCT00609804</DOCNO>
	<brief_summary>This randomize , open-label , multi-center , Phase II study treatment patient advance NSCLC progress erlotinib combination sorafenib erlotinib sorafenib alone .</brief_summary>
	<brief_title>Sorafenib Erlotinib Sorafenib Alone Advanced Non-Small Cell Lung Cancer Progressing Erlotinib</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Histologically confirm stage IIIB/IV relapse nonsmall cell lung carcinoma ( squamous carcinoma , adenocarcinoma , large cell carcinoma ) . Patients mixed tumor smallcell element ineligible . 2 . Patients 2 prior line therapy , late therapy singleagent erlotinib . 3 . Evidence progressive disease erlotinib assess treat physician . Erlotinib must last treatment NSCLC prior enrollment study . Patients may erlotinib enrollment . If erlotinib already stop , period time Erlotinib exceed 14 day prior study enrollment . 4 . Patients must experience clinical benefit ( complete response [ CR ] , partial response [ PR ] , stable disease [ SD ] ) prior therapy erlotinib period 8 week . 5 . Patient must one measurable lesion measure least 10 mm long diameter ( LD ) spiral compute tomography ( CT ) , 20 mm conventional technique accord Response Evaluation Criteria Solid Tumors ( RECIST ) . 6 . Recovery toxic effect erlotinib â‰¤ grade 1 per National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) . 7 . Completion palliative radiation therapy prior start study treatment . Previously irradiated lesion advance set include target lesion unless clear tumor progression observe follow completion radiation therapy . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . 9 . Absolute neutrophil count ( ANC ) &gt; =1,500 platelet &gt; =75,000 ( within 7 day prior initial study treatment ) . 10 . Hemoglobin &gt; =9 g/dL ( within 7 day prior initial treatment ) . 11. International normalize ratio ( INR ) &lt; =1.5 prothrombin time ( PT ) /partial thromboplastin time ( PTT ) within normal limit ( WNL ) institution anticoagulation therapy . Patients receive anticoagulation treatment agent warfarin heparin may allow participate therapeutic range establish prior study treatment initiation . 12 . Serum creatinine &lt; =1.5 x institutional upper limit normal ( ULN ) within 7 day prior initial study treatment . If absolute value great 2mg/dL , creatinine clearance , calculate accord CockroftGault formula , must &gt; =45 mL/min eligible . 13 . Bilirubin &lt; =1.5 x ULN ; transaminases &lt; =3 x institutional ULN , except know hepatic metastasis , wherein may &gt; =5 x institutional ULN . 14 . Patients must able understand nature study , give write informed consent , comply study requirement . 15 . Agreement male patient ( partner childbearing potential ) female patient childbearing potential use effective contraception prevent pregnancy treatment minimum 90 day thereafter . Additionally , woman breastfeed time . 1 . Past current history neoplasm entry diagnosis , exception treat nonmelanoma skin cancer carcinoma situ cervix , cancer cure local therapy alone , diseasefree survival ( DFS ) &gt; =3 year . 2 . Pregnancy lactation . All female childbearing potential must negative serum urine pregnancy test within 7 day prior study treatment . 3 . Prior epithelial growth factor receptor ( EGFR ) inhibitor , exception erlotinib , allow . This include tyrosine kinase inhibitor ( TKIs ) monoclonal antibody . Prior vascular endothelial growth factor ( VEGF ) inhibitor , exception bevacizumab , allow . 4 . Significant cardiac disease within 90 day start study treatment include : superior vena cava syndrome new onset angina congestive heart failure ( CHF ) &gt; Class 2 per New York Heart Association ( NYHA ) classification arrhythmia valvular heart disease . 5 . Myocardial infarction within 6 month prior initiation study treatment 6 . Cardiomegaly chest image ventricular hypertrophy electrocardiogram ( ECG ) unless leave ventricular ejection fraction ( LVEF ) within normal range institution . 7 . Poorly control hypertension ( define systolic blood pressure [ BP ] &gt; 150 mm Hg and/or diastolic BP &gt; 100 mm Hg antihypertensive medication ) . 8 . Unstable angina ( anginal symptom rest ) . 9 . Cardiac ventricular arrhythmia require antiarrhythmic therapy . 10 . Presence cardiac disease , opinion investigator , increase risk ventricular arrhythmia . 11 . A serious active infection ( &gt; grade 2 ) time treatment 12 . A serious underlying medical condition would impair ability patient receive protocol treatment . 13 . Untreated brain metastasis . Patients treated metastasis &gt; =4 week ( surgery and/or radiation therapy ) evidence central nervous system ( CNS ) progression eligible . 14 . Treatment nonapproved investigational drug within 28 day initial study treatment . 15 . A major surgical procedure , open biopsy , significant traumatic injury within 28 day begin treatment anticipation need major surgery course study . 16 . Thrombolic embolic event stroke transient ischemic attack ( TIA ) within past 6 month . 17 . Any prior history hypertensive crisis hypertensive encephalopathy . 18 . Pulmonary hemorrhage/bleeding event &gt; = grade 2 within 28 day initial study treatment . 19 . Any nonpulmonary hemorrhage/bleeding event &gt; = grade 3 within 28 day initial study treatment . 20 . Evidence history bleed diathesis coagulopathy . 21 . Serious nonhealing wound , ulcer , bone fracture . 22 . Use St. John 's Wort rifampin ( rifampicin ) . 23 . Known suspected allergy/hypersensitivity agent give course trial . 24 . Any malabsorption problem . 25 . Any condition impair patient 's ability swallow whole pill .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Advanced</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Progressing erlotinib</keyword>
</DOC>